your market intelligence analyst
Search Results
122 results
Your search is now limited to «Biogen» expert search.
MENAFN - GetNews) Creative Biogene, the world's leading biotechnology products and services provider, today announced the launch of its flagship offering lung cancer pathway products.
More from Middle East North Africa Financial Network (MENAFN):
ENDPOINTS 07/11/2019 17:48
The BACE theory of controlling Alzheimer’s died with failed pivotal projects at Merck , Eli Lilly and their partners at AstraZeneca. Now Amgen and Novartis have come along to bulldoze it under a mound of safety threats — leaving only Biogen and Eisai to carry on with a less than zero chance of success — with the notable addition that they may actually be doing harm to patients. After the market closed Thursday, Amgen and Novartis announced that they were dumping two pivotal programs underway with the Banner Alzheimer’s Institute on their BACE drug CNP520 (umibecestat) after an independent review of the data indicated that patients’ cognitive abilities were actually worsening at a faster pace than the placebo arm.
More from ENDPOINTS:
NASDAQ 07/08/2019 12:14
Price and EPS Surprise For Biogen, estimates have been trending higher, thanks in part to this earnings surprise history.
More from NASDAQ:
Contract Pharma 07/08/2019 11:10
Skyhawk Therapeutics, Inc. has expanded its collaboration with Biogen, extending Biogen's exclusive license to worldwide rights beyond the original research-stage therapeutic candidates for the treatment of conditions including multiple sclerosis (MS), spinal muscular atrophy (SMA) and additional neurological disorders, leveraging Skyhawk's SkySTAR technology platform ...
More from Contract Pharma:
Benzinga 07/01/2019 07:30
Biogen also continues to explore the scientific value of phosphorylated neurofilament heavy chain (pNF-H) and will present new data on the ongoing evaluation of its potential as a biomarker in SMA.
More from Benzinga:
FiercePharmaManufacturing 07/01/2019 07:21
With 'remarkable' data, Biogen's Spinraza sharpens its case against Novartis gene therapy.
More from FiercePharmaManufacturing:
GlobeNewswire 06/29/2019 04:00
Biogen announces European label update for SPINRAZA (nusinersen) which includes longer-term data across a broad range of ages and types of Spinal Muscular Atrophy.
More from GlobeNewswire:
24/7 Wall Street 06/28/2019 09:03
The top analyst upgrades, downgrades and initiations on Friday included Aerojet Rocketdyne, Apple, Baidu, Biogen, Chesapeake Energy, Chipotle Mexican Grill, McDonald's, Nike, Procter & Gamble and...
More from 24/7 Wall Street:
STAT 06/26/2019 15:59
But on Wednesday, Biogen said it was still analyzing the results from the nearly 3,000 patients in the aducanumab trials.
More from STAT:
Additional biogenic volatile organic compounds (BVOCs) are identified here.
More from International Journal of COPD:
Market Exclusive 06/20/2019 20:40
Biogen Inc. (NASDAQ:BIIB) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07 Submission of Matters to a Vote of Security Holders On June 19, 2019, Biogen Inc. (the \”Company\”) held its 2019 Annual Meeting of Stockholders. The final voting results for this meeting are as follows: About Biogen Inc. (NASDAQ:BIIB) Biogen […]. The post Biogen Inc. (NASDAQ:BIIB) Files An 8-K Submission of Matters to a Vote of Security Holders appeared first on Market Exclusive .
More from Market Exclusive:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications